Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Eosinophilic Esophagitis Market to Showcase Strong Growth Prospects Rising at a CAGR of 25.5% During the Study Period [2018-2030], Predicts DelveInsight

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

06 May, 2021, 17:30 GMT

Share this article

Share toX

Share this article

Share toX

The launch of emerging therapies such as Budesonide Oral Suspension, Dupilumab, Cendakimab, APT-1011, and others during the forecasted period 2021-2030 is predicted to boost the dynamics of the Eosinophilic Esophagitis market

LAS VEGAS, May 6, 2021 /PRNewswire/ -- DelveInsight's "Eosinophilic Esophagitis (EoE) Market" report provides a thorough comprehension of the Eosinophilic Esophagitis, historical and forecasted epidemiology, and the Eosinophilic Esophagitis market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Eosinophilic Esophagitis market report also proffers an analysis of the current Eosinophilic Esophagitis treatment algorithm/practice, market drivers, market barriers, and unmet medical needs. 

 Some of the imperative takeaways of the Eosinophilic Esophagitis Market Research Report  

  • A slew of companies such as EsoCap AG, Arena Pharmaceutical, GlaxoSmithKline, Dr Falk Pharma GmbH, Takeda, Regeneron Pharmaceuticals, Sanofi, Bristol-Myers Squibb, Ellodi Pharmaceuticals, AstraZeneca, Allakos, and others are developing therapies to influence Eosinophilic Esophagitis treatment outlook. 
  • Increased understanding of the clinical manifestations of the disease in conjunction with improved diagnosis and evolving treatment landscape will boost the Eosinophilic Esophagitis market landscape scenario.. 
  • The US FDA has granted priority review, breakthrough therapy designation, and orphan designation to Budesonide Oral Suspension (BOS) for the EoE treatment. 
  • In the Phase II study, RPC4046 demonstrated positive results. Currently, Bristol-Myers Squibb is conducting a Phase III clinical study to evaluate the efficacy and safety of CC-93538 in adult and adolescent participants with the indication.
  • APT-1011 has received orphan drug designation from the FDA. It is currently in Phase III development (FLUTE II), following the successful completion of its phase II study (FLUTE I) in 2019. 
  • Benralizumab is currently approved under the brand name Fasenra as an add-on maintenance treatment of severe asthma in patients aged ≥12 years and with an eosinophilic phenotype. Now, it is being evaluated in the Phase III study for the treatment of EoE. 
  • Currently, Lirentelimab is being evaluated in Phase II/III study for the Eosinophilic Esophagitis treatment in adult and adolescent subjects. The US FDA has granted orphan drug designation to antolimab for the treatment of EoE. 

 For further information on Market Impact by Therapies, visit: Eosinophilic Esophagitis Drug Market Analysis 

Eosinophilic Esophagitis (EoE) represents a chronic, local immune-mediated oesophagal disease, characterized clinically by symptoms related to oesophagal dysfunction and histologically by eosinophil-predominant inflammation. 

As per the estimates by DelveInsight, the total diagnosed Eosinophilic Esophagitis prevalent cases in 2020 were 547,924 cases. The highest prevalent cases were observed in the United States, accounting for approximately 58% of the total cases. 

The Eosinophilic Esophagitis Market Report provides historical as well as forecasted epidemiological analysis segmented into: 

  • Diagnosed Eosinophilic Esophagitis Prevalence
  • Gender-specific Eosinophilic Esophagitis Cases
  • Age-specific Eosinophilic Esophagitis Cases 

Get a sample copy of this report: Eosinophilic Esophagitis Market Size Landscape

Eosinophilic Esophagitis Treatment Market 

The Eosinophilic Esophagitis treatment involves Drugs, Diet, and Dilation. The first two components, which involve the use of proton pump inhibitors (PPIs), corticosteroids, immunosuppressant's, and empirical diets or guided food elimination based on allergy tests, are more useful in the initial phases. In contrast, endoscopic dilation is reserved for oesophagal strictures. 

Three dietary approaches for the management of EoE have emerged: the elemental diet, empiric dietary restrictions, and targeted dietary restrictions based on allergy testing.

PPIs are helpful as a first-line treatment for EoE patients. This therapy reduces acid production in the stomach and can reduce oesophagal inflammation. PPIs are recommended to be administered twice daily and continued for a minimum 2-month course after oesophagal eosinophilia is discovered. Afterwards, a repeat endoscopy with biopsies is performed to assess for persistent eosinophilic infiltration.

Corticosteroids, which control inflammation, are another effective therapy for the treatment of EoE. By swallowing small doses of corticosteroids, they contact and treat the inner lining of the oesophagus. Different forms of swallowed corticosteroids are available. The formulation of the most commonly used corticosteroids, including budesonide, fluticasone propionate, and ciclesonide, influences histological remission.

Oesophagal endoscopic dilation is most commonly used in adults with established oesophagal strictures. Although many physicians are fearful of dilating Eosinophilic Esophagitis patients due to concerns regarding mucosal tears and perforations, numerous case series attest to the safety and efficacy of oesophagal dilation.

The Food and Drug Administration currently approves no drugs for the EoE treatment. However, off-label medications have also been shown to reduce the number of eosinophils in the oesophagus and improve symptoms. 

Eosinophilic Esophagitis Emerging Therapies Along with Key Players

  • Budesonide Oral Suspension: Takeda
  • Dupilumab: Regeneron Pharmaceuticals/Sanofi
  • Cendakimab: Bristol-Myers Squibb
  • APT-1011: Ellodi Pharmaceuticals
  • Benralizumab: AstraZeneca
  • Lirentelimab: Allakos 

And several others.

Final thoughts on Eosinophilic Esophagitis Market Growth  

Eosinophilic Esophagitis Market Drivers such as increasing awareness, the emergence of non-invasive modalities, identification of biomarkers, development of animal models are responsible for Market Growth. In contrast, Eosinophilic Esophagitis Market Barriers such as high cost of treatment, lack of multidisciplinary management, and lack of optimal endpoint for treatment will nosedive the market size. 

Scope of the Eosinophilic Esophagitis Market Insight Report 

  • Geography Covered: The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 
  • Study Period: 3-year historical and 10-year forecasted analysis (2018-2030).
  • Eosinophilic Esophagitis Markets Segmentation: By Geographies and By Eosinophilic Esophagitis Therapies (Historical and Forecasted, Current and Upcoming) 
  • Dominant Market Companies investigating its candidates for Eosinophilic Esophagitis: EsoCap AG, Arena Pharmaceutical, GlaxoSmithKline, Dr Falk Pharma GmbH, Takeda, Regeneron Pharmaceuticals, Sanofi, Bristol-Myers Squibb, Ellodi Pharmaceuticals, AstraZeneca, Allakos, and several others. 
  • Analysis: Comparative and conjoint analysis of emerging therapies. 
  • Case Studies
  • KOL's Views
  • Analyst's View

Request for a Webex demo of the report @ Eosinophilic Esophagitis Treatment Market Size

Table of Contents 

1

Eosinophilic Esophagitis (EoE) Key Insights 

2

Eosinophilic Esophagitis Report Introduction

3

Eosinophilic Esophagitis Market Overview at a Glance

4

Eosinophilic Esophagitis Patient Split at a Glance

5

Executive Summary of Eosinophilic Esophagitis 

6

Eosinophilic Esophagitis Disease Background and Overview

7

EoE Treatment

8

Guidelines for Management of EoE 

9

Eosinophilic Esophagitis Epidemiology and Patient Population 

9.1

The United States

9.2

EU5 Countries

9.2.1

Germany

9.2.2

France

9.2.3

Italy

9.2.4

Spain

9.2.5

The United Kingdom

9.3

Japan

10

Organizations contributing toward the fight against EoE

11

EoE Patient Journey

12

Case Report

13

Eosinophilic Esophagitis Marketed Drug

13.1

Jorveza: Dr Falk Pharma GmbH

14

Eosinophilic Esophagitis Emerging Drugs

14.1

Budesonide Oral Suspension: Takeda

14.2

Dupilumab: Regeneron Pharmaceuticals/Sanofi

14.3

Cendakimab: Bristol-Myers Squibb

14.4

APT-1011: Ellodi Pharmaceuticals

14.5

Benralizumab: AstraZeneca

14.6

Lirentelimab: Allakos

15

Other Promising Therapies

15.1

ESO-101: EsoCap AG

15.2

Etrasimod: Arena Pharmaceutical

15.3

Mepolizumab: GlaxoSmithKline

16

7MM Eosinophilic Esophagitis Market Analysis

16.1

The United States Eosinophilic Esophagitis Market Size

16.2

EU-5 Eosinophilic Esophagitis Market Size

16.2.1

Germany Market Size

16.2.2

France Market Size

16.2.3

Italy Market Size

16.2.4

Spain Market Size

16.2.5

The United Kingdom Market Size

16.3

Japan Eosinophilic Esophagitis Market Size

17

KOL Views

18

Eosinophilic Esophagitis Market Drivers

19

Eosinophilic Esophagitis Market Barriers

20

SWOT Analysis of Eosinophilic Esophagitis

21

Eosinophilic Esophagitis Unmet Needs

22

Appendix

23

DelveInsight Capabilities

24

Disclaimer

25

About DelveInsight

Browse full report with detailed TOC with charts, figures, tables @ Eosinophilic Esophagitis Market Share Report

View Related Reports  

  • Eosinophilic Esophagitis Epidemiology Forecast 

DelveInsight's Eosinophilic Esophagitis - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Eosinophilic Esophagitis. 

  • Eosinophilic Esophagitis Pipeline

Eosinophilic Esophagitis Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Eosinophilic Esophagitis market.

  • Erosive Esophagitis Market

DelveInsight's Erosive Esophagitis (EE) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology of Eosinophilic Esophagitis.

  • Esophageal Cancer Market

DelveInsight's Esophageal Cancer - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

  • Radiation-induced Esophagitis Market 

DelveInsight's Radiation-induced Esophagitis - Market Insights, Epidemiology and Market Forecast - 2030 report provides a depth understanding of historical and forecasted epidemiology.

  • Gastro-Esophageal Junction Neuroendocrine Tumor (GEJ-NET) Market

DelveInsight's 'Gastro-Esophageal Junction Neuroendocrine Tumor (GEJ-NET) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease historical & forecasted epidemiology, as well as the market trends of GEJ-NET in the 7MM.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Business Consulting Services with a credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach. 

Contact Us:

Shruti Thakur
info@delveinsight.com  
+1(919)321-6187
www.delveinsight.com 

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

Modal title

Also from this source

Rett Syndrome Market Sees Momentum with Novel Gene and Protein-Targeted Therapies | DelveInsight

Rett Syndrome Market Sees Momentum with Novel Gene and Protein-Targeted Therapies | DelveInsight

Rett syndrome is a rare genetic neurological condition that typically emerges in infancy and primarily affects girls, though occasional cases have...

Johnson & Johnson's IMAAVY Gets FDA Approval, Taking on Top Players in Myasthenia Gravis Market | DelveInsight

Johnson & Johnson's IMAAVY Gets FDA Approval, Taking on Top Players in Myasthenia Gravis Market | DelveInsight

Myasthenia gravis is an autoimmune disorder in which antibodies disrupt the communication between nerves and muscles, resulting in skeletal muscle...

More Releases From This Source

Explore

Pharmaceuticals

Pharmaceuticals

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.